Bench validated in cancer cell lines
The validated GIPZ lentiviral shRNAmir cancer set was developed with funding from the National Cancer Institute (NCI) to test and validate shRNAs targeting a set of high priority human cancer genes. After validation, the sequences of the cancer gene-associated shRNAs have been deposited into the NCI's Cancer Genome Anatomy Project (CGAP) open access public database and are commercially available through Open Biosystems. The validated shRNAs will serve as tools for researchers to target and modulate the expression of well-known cancer-associated genes.Highlights of the set include:- Targets important cancer specific genes with three shRNA per gene
- shRNAmir design increases specificity and knockdown efficiency
- Bench validated in two cancer cell lines
- Efficient knockdown at low copy
- Guaranteed* knockdown
All the GIPZ shRNAmir included in the validated cancer set were validated at low multiplicity of infection (MOI= 0.4-2). The level of knockdown for a shRNAmir to be considered successfully validated was set to ≥50% of mRNA expression. Over 80% of genes tested had at least one shRNAmir that produced ≥50% knockdown.
The validated GIPZ lentiviral shRNAmir human cancer set is available as individual GIPZ shRNAmir, target gene sets, or the entire validated set. Only those shRNAmir that produced ≥50% knockdown in at least one cell line have been included in the set.
See Data table for a list of all GIPZ lentiviral shRNAmir included in the study.
Download poster presentation for detailed protocols and results.
This validation data is also available through the Cancer Gene Anatomy Project (CGAP) RNAi website at the National Cancer Institute.
* when purchased with RNAintro starter kit
This product is covered by a Limited Use License
TurboGFP is covered by a Limited Use License from Evrogen.
Shipping Information:
The validated human GIPZ lentiviral shRNAmir cancer set is provided in 96-well microtiter plates containing frozen stock cultures of E.coli in LB (low salt) broth with 8% glycerol, carbenicillin (100ug/ml) and zeocin (25ug/ml). Individual shRNAmir constructs are shipped as glycerol stock cultures on wet ice. Open Biosystems checks all cultures for growth prior to shipment. Store at -80ºC.
References:
- Stegmeier F et al (2005) "A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells" PNAS Vol 102:37; 13212-13217.
- Yamamoto T. and Y. Tsunetsugu-Yokota (2008) "Prospects for the therapeutic application of lentivirus-based gene therapy to HIV-1 infection" Curr Gene Ther. Vol 8:1; 1-8.
